Overview

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Status:
NOT_YET_RECRUITING

Trial end date:
2027-05-31

Target enrollment:

Participant gender:

Summary

This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Cancer Hospital

Treatments:

anlotinib